TD Cowen maintains Arcutis Biotherapeutics at Buy, raises price target to $40 from $35
TD Cowen kept its Buy rating on Arcutis Biotherapeutics and increased its price target to $40 from $35, citing a 17.5% upside from the Nov 4 close of $34.05.
How this was made

The 30-second read
Why it matters
Analyst price target increase may prompt short-term buying.
Market read
Analyst upgrade provides modest new information for traders.
What to watch
No new clinical data released; upgrade based on analyst opinion only.
Background
Arcutis Biotherapeutics is a clinical-stage biotech focused on dermatology.
Market effects
May boost sentiment in biotech sector.
Limited to US biotech investors.
Minimal global impact.
Counterpoint
Target raise could be premature if upcoming trial data disappoints.
Key entities
- AnalystTD Cowen
Equity research firm issuing the rating.
